Altimmune, Inc., a clinical stage biopharmaceutical company based in Gaithersburg, Maryland, focuses on developing peptide-based therapeutics for obesity and liver diseases, including a dual receptor agonist, pemvidutide, for obesity and NASH, and an immunotherapeutic agent, HepTcell, for chronic hepatitis B. The company, which went public in 2005 and employs 52 people, has subsidiaries in the U.S., U.K., and Australia, and is currently conducting Phase II trials for HepTcell across several countries.
ALT has been in the news recently: Altimmune, Inc. is facing potential claims and lawsuits for violating federal securities laws, with investors reminded of the July 5, 2024 deadline to seek lead plaintiff role in a class action lawsuit. Shareholders are advised to monitor Altimmune's cash burn rate and potential need for additional funding in the future.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
